SNTI
Senti Biosciences, Inc.
There isn't enough reported data to score SNTI yet.
SNTI Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
SNTI's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
SNTI PE Valuation
SNTI has no meaningful PE right now: it lost money over the past year.
SNTI Forward outlook
There aren't enough analyst estimates for SNTI to show an outlook.
SNTI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$27.34 | -$6.04 |
| Q2 2024 | -$24.43 | -$2.73 |
| Q1 2024 | -$26.18 | -$0.08 |
SNTI is still losing money, but far less than before: $1.79 per share over the past year, against $27.78 at its worst in late 2023.
SNTI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2023 | $338K | -81% |
| Q2 2023 | $937K | -31% |
| Q4 2022 | $59K | -93% |
| Q4 2021 | $793K | +39550% |
SNTI's revenue has slid since its 2022 peak: $17,000 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -85229% | N/A |
| Q1 2026 | -28850% | N/A |
| Q3 2023 | -12981% | -12014 points |
| Q2 2023 | -2096% | -492 points |
| Q1 2023 | -1542% | N/A |
| Q4 2022 | -33925% | -32553 points |
| Q3 2022 | -967% | N/A |
| Q2 2022 | -1603% | N/A |
SNTI's operating margin was −85229% last quarter, down 83687 points from the same quarter a year ago, near the bottom of its range since 2020.
SNTI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$7.5M | +$6.6M |
| Q4 2025 | -$6.9M | +$6.6M |
| Q3 2025 | -$9.4M | -$1.6M |
| Q2 2025 | -$13.3M | -$4.9M |
| Q1 2025 | -$14.1M | -$2.4M |
| Q4 2024 | -$13.5M | -$6.5M |
| Q3 2024 | -$7.9M | +$9.4M |
| Q2 2024 | -$8.3M | +$9M |
SNTI has burned cash in almost every quarter: −$37M over the past year, against −$44M the year before.
SNTI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +173K shares |
| 1 year | +211% | +21.1M shares |
| 3 years | +607% | +26.7M shares |
SNTI has 31M diluted shares, up 211% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
SNTI Net Leverage
SNTI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SNTI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.7 | Oversold |
| Stochastic | 3.2 | Oversold |
SNTI's weekly RSI is 25 (oversold) and its Stochastic is 3 (oversold).
SNTI PE vs Healthcare Sector
SNTI has no meaningful PE right now: it lost money over the past year.
SNTI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.23 | 35% below |
| 20 week MA | $0.38 | 61% below |
| 50 week MA | $0.77 | 81% below |
| 100 week MA | $1.79 | 92% below |
| 200 week MA | $3.87 | 96% below |
SNTI is in a downtrend: it's below all five of its weekly moving averages, and 96% below its 200-week average.
SNTI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $100.0 | $98.5 | -1.5% |
| 2022 | $98.5 | $13.4 | -86% |
| 2023 | $13.4 | $6.60 | -51% |
| 2024 | $6.60 | $3.92 | -41% |
| 2025 | $3.92 | $1.06 | -73% |
| 2026 YTD | $1.06 | $0.15 | -86% |
SNTI has finished every year since 2021 lower, and it's down 86% so far in 2026.